Market open
Alto Neuroscience/$ANRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alto Neuroscience
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Ticker
$ANRO
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
76
ISIN
US02157Q1094
Website
ANRO Metrics
BasicAdvanced
$60M
-
-$2.50
-
-
Price and volume
Market cap
$60M
52-week high
$17.55
52-week low
$1.60
Average daily volume
257K
Financial strength
Current ratio
16.92
Quick ratio
16.809
Long term debt to equity
10.613
Total debt to equity
11.187
Interest coverage (TTM)
-49.90%
Management effectiveness
Return on assets (TTM)
-32.46%
Return on equity (TTM)
-55.19%
Valuation
Price to book
0.39
Price to tangible book (TTM)
0.39
Price to free cash flow (TTM)
-1.093
Growth
Earnings per share change (TTM)
-74.34%
3-year earnings per share growth (CAGR)
-13.11%
What the Analysts think about ANRO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.
ANRO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ANRO News
AllArticlesVideos
Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach
Business Wire·2 weeks ago
Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day
Business Wire·3 weeks ago
The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Alto Neuroscience stock?
Alto Neuroscience (ANRO) has a market cap of $60M as of May 15, 2025.
What is the P/E ratio for Alto Neuroscience stock?
The price to earnings (P/E) ratio for Alto Neuroscience (ANRO) stock is 0 as of May 15, 2025.
Does Alto Neuroscience stock pay dividends?
No, Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next Alto Neuroscience dividend payment date?
Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Alto Neuroscience?
Alto Neuroscience (ANRO) does not currently have a Beta indicator.